| Model Number |
305U23 |
| Medical Device Problem Codes |
Calcified (1077); Gradient Increase (1270); Insufficient Device Problem Information (3190); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Codes |
Calcium Deposits/Calcification (1758); Aortic Valve Insufficiency/ Regurgitation (4450); Insufficient Information (4580)
|
| Date of Event |
01/08/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that 12 years and 11 months post implant of this 23mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.No intervention or adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
B1, b2, b5, h1 and imf (annex f) updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information received reported on january 20, 2026 the patient successfully had a 23mm aortic transcatheter valve-in-valve replacement.No additional adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
Additional information was received that the reason for intervention was due to calcium build up, high gradient and severe aortic regurgitation.No additional adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
B2, b5 and h6 updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|